Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Bristol-Myers Squibb Stock

Price
Target price
€43.94

€43.94

1.600%
0.69
1.600%
€55.50
 
19:17 / Tradegate WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Bristol-Myers Squibb in the next few years
Wizard

Bristol-Myers Squibb Stock

There is an upward development for Bristol-Myers Squibb compared to yesterday, with an increase of €0.69 (1.600%).
Currently there is a rather positive sentiment for Bristol-Myers Squibb with 9 Buy predictions and 3 Sell predictions.
As a result the target price of 55 € shows a positive potential of 25.18% compared to the current price of 43.94 € for Bristol-Myers Squibb.
For the coming years our community has positive and negative things to say abot the Bristol-Myers Squibb stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Business model" there were negative voices in the community.
What does Bristol-Myers do?

Pros and Cons of Bristol-Myers Squibb in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Bristol-Myers Squibb vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Bristol-Myers Squibb 1.600% -0.791% -21.856% 3.867% -21.444% -39.416% -23.690%
Elanco Animal Health Inc. -2.950% 9.822% -11.090% -32.401% -25.927% -64.381% -62.809%
Johnson & Johnson 0.040% -0.826% -9.371% -0.029% -1.539% -20.012% -0.869%
Biogen Inc. 0.380% 1.441% -17.274% -47.489% -26.692% -46.314% -62.319%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26

Bristol Myers Squibb Co. (BMY) has reported its Q2 2025 financial results as of March 31, 2025. The company's current financial position shows a mixed trend with both positive and challenging indicators.

Key Findings: * Revenue decreased to $11.201 billion from $11.865 billion in the same quarter last year * Net profit significantly improved to $2.456 billion compared to a loss of $11.911 billion in Q2 2024 * Cash and cash equivalents increased to $10.875 billion from $9.334 billion as of March 31, 2024

Overall Trend: Mixed, with improving profitability but declining revenue.

Show more

Comments

Prediction Buy
Perf. (%) 5.75%
Target price 59.588
Change
Ends at 23.04.26

Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more

Jefferies Financial Group Inc. 
0
Report Share
23.04.25

Bristol-Myers Squibb (NYSE: BMY) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more

Piper Sandler 
0
Report Share
22.04.25 Buy 3.88%
Prediction Buy
Perf. (%) -20.66%
Target price 63.057
Change
Ends at 08.01.26

Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Truist Financial Co. from $62.00 to $65.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
08.01.25
Show more
Not a member yet? Sign up for free!

News

Bristol-Myers Squibb Stock: $286M Acquisition Targets Cancer Therapy
Bristol-Myers Squibb Stock: $286M Acquisition Targets Cancer Therapy

Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share in an all-cash transaction. The deal values 2seventy bio at approximately

StockWorldEnglish 
0 11.03.25